Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600196's EV-to-FCF is ranked worse than 90.52% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.58
vs SHSE:600196: 136.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Fosun Pharmaceutical (Group) Co's PE Ratio (TTM) for today is calculated as:
Shanghai Fosun Pharmaceutical (Group) Co's share price for today is ¥22.87.
Shanghai Fosun Pharmaceutical (Group) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-FCF Related Terms
Shanghai Fosun Pharmaceutical (Group) Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-FCF Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-FCF vs Drug Manufacturers Industry
Shanghai Fosun Pharmaceutical (Group) Co's current Enterprise Value is ¥95,792 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥700 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a EV-to-FCF of 136.89 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #506 out of 559 companies in the Drug Manufacturers industry, placing it in the top 90.5%.
Is Shanghai Fosun Pharmaceutical (Group) Co's EV-to-FCF too high?
Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-FCF is 136.89. The Drug Manufacturers industry median EV-to-FCF is 20.58. Shanghai Fosun Pharmaceutical (Group) Co's value of 136.89 is 565.2% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #506 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #506 out of 559 companies for EV-to-FCF. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median EV-to-FCF is 20.58. Shanghai Fosun Pharmaceutical (Group) Co's value of 136.89 is 565.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.58, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-FCF of 136.89 is 565.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-FCF is 136.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥26.29, compared to a current price of ¥22.87 — trading 13% below its estimated fair value. The current EV-to-FCF is 136.89 and 565.2% above the Drug Manufacturers industry median of 20.58. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current EV-to-FCF is 136.89 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of ¥22.87 is trading 13% below its estimated GF Value™ of ¥26.29.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600196:
EV-to-FCF: 136.89
GF Value™: ¥26.29 vs. price of ¥22.87 (13% below fair value)
Industry Position: 565.2% above the Drug Manufacturers median (#506 of 559)
No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
82GF Score
Get the complete analysis for SHSE:600196
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600196 has been successfully added to your 
